Research and Clinical Trials
The Dartmouth-Hitchcock Rheumatology Team participates in the study of new drugs to treat rheumatoid and psoriatic arthritis, as well as other conditions.
Our team also consists of research faculty located at the VA in White River Junction, VT.
A clinical trial is a research study in which people can participate. The purpose of a clinical trial is to study the effectiveness of a treatment, medication, experimental drug, or device.
The following is a list of clinical trials with which the Section of Rheumatology at Dartmouth-Hitchcock Medical Center is currently involved. Talk to your doctor to find out if a clinical trial is right for you.
Rheumatology Clinical Trials
A Long-Term, Open-Label Extension Study Of Tofacitinib (Cp-690,550) For The Treatment Of Psoriatic Arthritis (A3921092)
A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis
A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults with Active Idiopathic Inflammatory Myopathy (IIM)
A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX
A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects with Active Psoriatic Arthritis
A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
Treatments Against RA and Effect on FDG PET-CT: The TARGET Trial
Validation of VISTA, a Negative Regulator as a Novel Therapy for Autoimmune Disease